ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
ImmunityBio, Inc. (IBRX)
Company Research
Source: GlobeNewswire
SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio’s lead biologic product (Anktiva), which the FDA said were misleading efficacy claims. This news drove the price of ImmunityBio shares down over 21% on March 24, 2026. The developments have prompted national shareholders rights firm Hagens Berman to investigate claims that ImmunityBio violated the federal securities laws. The firm urges investors in ImmunityBio who suffered significant losses to submit your losses now. The firm also encourages witnesses who may be able to assist in the investigation to contact it
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026GlobeNewswire
- ImmunityBio: No Need To Rush Into Buying Today - Why I'm Downgrading To Hold [Seeking Alpha]Seeking Alpha
- Deadline Approaching: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithBusiness Wire
- IBRX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire
- NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.GlobeNewswire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 4/2/26 - Form 4
- 3/31/26 - Form 8-K
- 2/26/26 - Form 4
- IBRX's page on the SEC website